
Validea's guru fundamental report rated Abbott Laboratories (ABT) at 75% using Pim van Vliet's Multi-Factor Investor model, which prioritizes low volatility, strong momentum, and high net payout yields. Despite ABT's large-cap status and low volatility characteristics, the 75% score falls below the 80% threshold for 'some interest,' and the stock ultimately received a 'FAIL' on its final rank within this strategy, indicating it does not fully align with all of the model's quantitative investment criteria.
Abbott Laboratories (ABT) was evaluated using Validea's quantitative model based on Pim van Vliet's multi-factor strategy, which targets low-volatility stocks with strong momentum and high net payout yields. The stock received an overall score of 75%, falling below the 80% threshold that indicates model interest. While ABT passed the criteria for large market capitalization and low standard deviation, aligning with the conservative factor premise of the strategy, it was rated 'NEUTRAL' on both its 'Twelve Minus One Momentum' and 'Net Payout Yield'. These neutral findings on key return-driving factors ultimately led the model to assign a 'FAIL' to the stock's final rank, an assessment reflected in the mildly negative sentiment score of -0.4. This indicates that despite its low-risk characteristics, ABT's current profile does not meet the combined criteria for this specific factor-based investment approach.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment